{
    "title": "115_hr4724",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Medicare IVIG Access Enhancement \nAct''.\n\nSEC. 2. MEDICARE PATIENT IVIG ACCESS DEMONSTRATION PROJECT.\n\n    (a) Establishment.--The Secretary of Health and Human Services (in \nthis section referred to as the ``Secretary'') shall establish and \nimplement a demonstration project under part B of title XVIII of the \nSocial Security Act to evaluate the benefits of providing payment for \nitems and services needed for the in-home administration of intravenous \nimmune globulin for the treatment of chronic inflammatory demyelinating \npolyneuropathy or multifocal motor neuropathy.\n    (b) Duration and Scope.--\n            (1) Duration.--Beginning not later than 1 year after the \n        date of enactment of this Act, the Secretary shall conduct the \n        demonstration project for a period of 3 years.\n            (2) Scope.--The Secretary shall enroll not greater than \n        3,000 Medicare beneficiaries who have been diagnosed with \n        chronic inflammatory demyelinating polyneuropathy or multifocal \n        motor neuropathy for participation in the demonstration \n        project. A Medicare beneficiary may participate in the \n        demonstration project on a voluntary basis and may terminate \n        participation at any time.\n    (c) Coverage.--Except as otherwise provided in this section, items \nand services for which payment may be made under the demonstration \nprogram shall be treated and covered under part B of title XVIII of the \nSocial Security Act in the same manner as similar items and services \ncovered under such part.\n    (d) Payment.--\n            (1) Intravenous immune globulin.--For intravenous immune \n        globulin furnished under this section, the Secretary shall make \n        payment using the payment methodology under section 1847A of \n        the Social Security Act (42 U.S.C. 1395w-3a).\n            (2) Other items and services.--\n                    (A) In general.--The Secretary shall establish, \n                subject to subparagraph (B), a per-visit payment amount \n                for items and services (other than intravenous immune \n                globulin) needed for the in-home infusion of \n                intravenous immune globulin for the treatment of \n                chronic inflammatory demyelinating polyneuropathy or \n                multifocal motor neuropathy based on the national per \n                visit low-utilization payment amount under the \n                prospective payment system for home health services \n                established under section 1895 of the Social Security \n                Act (42 U.S.C. 1395fff).\n                    (B) Limitation.--The per-visit payment amount \n                established under subparagraph (A) for items and \n                services described in such subparagraph shall not be \n                less than the payment amount applied under the \n                demonstration project established under section 101 of \n                the Medicare IVIG Access and Strengthening Medicare and \n                Repaying Taxpayers Act of 2012 (Public Law 112-242) for \n                comparable items and services needed for the in-home \n                administration of intravenous immune globulin for the \n                treatment of primary immune deficiency diseases.\n    (e) Waiver Authority.--The Secretary may waive such requirements of \ntitle XVIII of the Social Security Act as may be necessary to carry out \nthe demonstration project.\n    (f) Reports to Congress.--\n            (1) Interim evaluation and report.--Not later than 3 years \n        after the date of enactment of this Act, the Secretary shall \n        submit to Congress a report that contains--\n                    (A) an evaluation of the impact of the \n                demonstration project on access for Medicare \n                beneficiaries with chronic inflammatory demyelinating \n                polyneuropathy and Medicare beneficiaries with \n                multifocal motor neuropathy to items and services \n                needed for the in-home administration of intravenous \n                immune globin; and\n                    (B) an analysis of the appropriateness of expanding \n                or extending the demonstration project or implementing \n                a new methodology for payment for intravenous immune \n                globulins in all care settings under part B of title \n                XVIII of the Social Security Act (42 U.S.C. 1395k et \n                seq.) and, to the extent such analysis determines such \n                an expansion, extension, or methodology appropriate, \n                recommendations for such expansion, extension, or \n                methodology, respectively.\n            (2) Final evaluation and report.--Not later than one year \n        after the date of completion of the demonstration project, the \n        Secretary shall submit to Congress a report that contains--\n                    (A) a final evaluation of the impact described in \n                paragraph (1)(A); and\n                    (B) a final analysis and recommendations described \n                in paragraph (1)(B).\n    (g) Definitions.--In this section:\n            (1) Demonstration project.--The term ``demonstration \n        project'' means the demonstration project conducted under this \n        Act.\n            (2) Medicare beneficiary.--The term ``Medicare \n        beneficiary'' means an individual who is enrolled for benefits \n        under part B of title XVIII of the Social Security Act."
}